research:all_by_all_incidence
Differences
This shows you the differences between two versions of the page.
| Both sides previous revision Previous revision Next revision | Previous revision Last revision Both sides next revision | ||
|
research:all_by_all_incidence [2017/11/30 22:45] rchen |
research:all_by_all_incidence [2017/11/30 22:50] rchen |
||
|---|---|---|---|
| Line 3: | Line 3: | ||
| <WRAP box justify round> | <WRAP box justify round> | ||
| - | **Objective:** //<summarize study objective>// | + | **Objective:** To identify the incidence of clinical conditions/diagnoses following initiation of a given drug. We will systematically calculate incidence rate and incidence proportion for all drugs and all conditions across various times-at-risk and the inclusion/exclusion of patients with incomplete time-at-risk. This analysis will be executed across multiple databases and both summarized numerically and graphically from an aggregate table as well as detailed for each individual database. These results will then be shared via a searchable, public web site. |
| - | **Rationale:** //<summarize study rationale>// | + | **Rationale:** Although drugs often undergo extensive testing during clinical trials, little is known about the real world incidence of conditions following initiation of a given drug. The limited evidence which does exist is often marred by poorly defined target cohorts, time-at-risk, and statistical metrics for incidence, along with wide variations across the literature. Therefore, what should be a simple question, “What is the likelihood I will experience a condition after starting this drug?” is difficult for patients and clinicians to answer. |
| - | **Project Lead(s):** //<initial proposers, list may grow>// | + | **Project Lead(s):** George Hripcsak, Patrick Ryan |
| - | **Coordinating Institution(s):** //<your institution>// | + | **Coordinating Institution(s):** Columbia University, Janssen R&D |
| - | ** Additional Participants:** //<usually blank initially, list will grow as individuals are added who are not project leads>// | + | ** Additional Participants:** |
| **Full Protocol:** //<if available, a link to protocol. not necessary for initial planning>// | **Full Protocol:** //<if available, a link to protocol. not necessary for initial planning>// | ||
| - | **Initial Proposal Date:** | + | **Initial Proposal Date: ** 10/18/2017 |
| - | **Launch Date:** //<fill out once finalized>// | + | **Launch Date: ** TBD |
| - | **Study Closure Date: //<fill out once finalized>//** | + | **Study Closure Date: ** TBD |
| - | **Results Submission:** //<method of sumission, eg. [[mailto:contact@ohdsi.org|Email]] or SFTP>// | + | **Results Submission:** SFTP |
| </WRAP> | </WRAP> | ||
| ===== Requirements ===== | ===== Requirements ===== | ||
| - | **CDM:** //<V4 or V5 or both>// | + | **CDM:** V5 |
| - | **Table Accessed:** //<e.g., person, drug_exposure, observations>// | + | **Table Accessed:** |
| - | **Database Dialects:** SQL Server, Postgres, Oracle | + | **Database Dialects:** Microsoft SQL Server, Postgres, Oracle, Redshift |
| - | **Software:** //<<e.g., R>// | + | **Software:** R |
| ===== Code ===== | ===== Code ===== | ||
| Line 41: | Line 41: | ||
| ===== Datasets Run ===== | ===== Datasets Run ===== | ||
| - | * <list your own datasets or leave blank> | + | * Columbia University |
| ~~NOTOC~~ | ~~NOTOC~~ | ||
research/all_by_all_incidence.txt · Last modified: 2017/12/07 21:01 by rchen
Page Tools
